APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Multiple Sclerosis (MS) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Multiple Sclerosis (MS) Drugs Market Analysis and Forecast 2026-2032

Report ID 174014840226 December 2025209 pages

Choose your research edition.

Industry ResearchMultiple Sclerosis (MS) Drugs Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Multiple Sclerosis (MS) Drugs Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Multiple Sclerosis (MS) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multiple Sclerosis (MS) Drugs Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Multiple Sclerosis (MS) Drugs Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Multiple Sclerosis (MS) Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Multiple Sclerosis (MS) Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Multiple Sclerosis (MS) Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Multiple Sclerosis (MS) Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Multiple Sclerosis (MS) Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Multiple Sclerosis (MS) Drugs include Eli Lilly, Bayer AG, Innate Immunotherapeutics, Gw Pharmaceuticals, Glaxosmithkline, Genzyme, Genmab, Five Prime Therapeutics and Fast Forward Llc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Multiple Sclerosis (MS) Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Multiple Sclerosis (MS) Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Multiple Sclerosis (MS) Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Multiple Sclerosis (MS) Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Multiple Sclerosis (MS) Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Multiple Sclerosis (MS) Drugs sales, projected growth trends, production technology, application and end-user industry.

Multiple Sclerosis (MS) Drugs Segment by Company

Eli Lilly

Bayer AG

Innate Immunotherapeutics

Gw Pharmaceuticals

Glaxosmithkline

Genzyme

Genmab

Five Prime Therapeutics

Fast Forward Llc

Daiichi Sankyo

Cinnagen

Biogen Idec

Bayhill Therapeutics

Artielle Immunotherapeutics

Apitope

Antisense Therapeutics

Multiple Sclerosis (MS) Drugs Segment by Type

Copaxone (Glatiramer Acetate, Copolymer 1)

Firategrast (Sb683699, T-0047)

Gilenya (Fingolimod, Fty720)

Tecfidera (Dimethyl Fumarate)

Aubagio (Teriflunomide)

Siponimod (Baf312)

Novantrone (Mitoxantrone)

Others

Multiple Sclerosis (MS) Drugs Segment by Application

PPMS

PRMS

RRMS

SPMS

Multiple Sclerosis (MS) Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multiple Sclerosis (MS) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multiple Sclerosis (MS) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multiple Sclerosis (MS) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Multiple Sclerosis (MS) Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Multiple Sclerosis (MS) Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Multiple Sclerosis (MS) Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Multiple Sclerosis (MS) Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Copaxone (Glatiramer Acetate, Copolymer 1) Major Manufacturers Table 3. Firategrast (Sb683699, T-0047) Major Manufacturers Table 4. Gilenya (Fingolimod, Fty720) Major Manufacturers Table 5. Tecfidera (Dimethyl Fumarate) Major Manufacturers Table 6. Aubagio (Teriflunomide) Major Manufacturers Table 7. Siponimod (Baf312) Major Manufacturers Table 8. Novantrone (Mitoxantrone) Major Manufacturers Table 9. Others Major Manufacturers Table 10. Global Multiple Sclerosis (MS) Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 11. PPMS Major Manufacturers Table 12. PRMS Major Manufacturers Table 13. RRMS Major Manufacturers Table 14. SPMS Major Manufacturers Table 15. Multiple Sclerosis (MS) Drugs Industry Trends Table 16. Multiple Sclerosis (MS) Drugs Industry Drivers Table 17. Multiple Sclerosis (MS) Drugs Industry Opportunities and Challenges Table 18. Multiple Sclerosis (MS) Drugs Industry Restraints Table 19. Global Multiple Sclerosis (MS) Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Multiple Sclerosis (MS) Drugs Revenue by Region (2021-2026) & (US$ Million) Table 21. Global Multiple Sclerosis (MS) Drugs Revenue by Region (2027-2032) & (US$ Million) Table 22. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Region (2021-2026) Table 23. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Region (2027-2032) Table 24. Global Multiple Sclerosis (MS) Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (W Units) Table 25. Global Multiple Sclerosis (MS) Drugs Sales by Region (2021-2026) & (W Units) Table 26. Global Multiple Sclerosis (MS) Drugs Sales by Region (2027-2032) & (W Units) Table 27. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Region (2021-2026) Table 28. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Region (2027-2032) Table 29. Global Multiple Sclerosis (MS) Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 30. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Manufacturers (2021-2026) Table 31. Global Multiple Sclerosis (MS) Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 32. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Manufacturers (2021-2026) Table 33. Global Multiple Sclerosis (MS) Drugs Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 34. Global Multiple Sclerosis (MS) Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 35. Global Multiple Sclerosis (MS) Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 36. Global Multiple Sclerosis (MS) Drugs Manufacturers, Product Type & Application Table 37. Global Multiple Sclerosis (MS) Drugs Manufacturers' Establishment Date Table 38. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 39. Global Multiple Sclerosis (MS) Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Multiple Sclerosis (MS) Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Multiple Sclerosis (MS) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 42. Global Multiple Sclerosis (MS) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 43. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2021-2026) Table 44. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2027-2032) Table 45. Global Multiple Sclerosis (MS) Drugs Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 46. Global Multiple Sclerosis (MS) Drugs Sales by Type (2021-2026) & (W Units) Table 47. Global Multiple Sclerosis (MS) Drugs Sales by Type (2027-2032) & (W Units) Table 48. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2021-2026) Table 49. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2027-2032) Table 50. Global Multiple Sclerosis (MS) Drugs Price by Type (2021-2026) & (US$/Unit) Table 51. Global Multiple Sclerosis (MS) Drugs Price by Type (2027-2032) & (US$/Unit) Table 52. Global Multiple Sclerosis (MS) Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Multiple Sclerosis (MS) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 54. Global Multiple Sclerosis (MS) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 55. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2021-2026) Table 56. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2027-2032) Table 57. Global Multiple Sclerosis (MS) Drugs Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 58. Global Multiple Sclerosis (MS) Drugs Sales by Application (2021-2026) & (W Units) Table 59. Global Multiple Sclerosis (MS) Drugs Sales by Application (2027-2032) & (W Units) Table 60. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2021-2026) Table 61. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2027-2032) Table 62. Global Multiple Sclerosis (MS) Drugs Price by Application (2021-2026) & (US$/Unit) Table 63. Global Multiple Sclerosis (MS) Drugs Price by Application (2027-2032) & (US$/Unit) Table 64. Eli Lilly Company Information Table 65. Eli Lilly Business Overview Table 66. Eli Lilly Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Eli Lilly Multiple Sclerosis (MS) Drugs Product Portfolio Table 68. Eli Lilly Recent Development Table 69. Bayer AG Company Information Table 70. Bayer AG Business Overview Table 71. Bayer AG Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Bayer AG Multiple Sclerosis (MS) Drugs Product Portfolio Table 73. Bayer AG Recent Development Table 74. Innate Immunotherapeutics Company Information Table 75. Innate Immunotherapeutics Business Overview Table 76. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio Table 78. Innate Immunotherapeutics Recent Development Table 79. Gw Pharmaceuticals Company Information Table 80. Gw Pharmaceuticals Business Overview Table 81. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Portfolio Table 83. Gw Pharmaceuticals Recent Development Table 84. Glaxosmithkline Company Information Table 85. Glaxosmithkline Business Overview Table 86. Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Portfolio Table 88. Glaxosmithkline Recent Development Table 89. Genzyme Company Information Table 90. Genzyme Business Overview Table 91. Genzyme Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Genzyme Multiple Sclerosis (MS) Drugs Product Portfolio Table 93. Genzyme Recent Development Table 94. Genmab Company Information Table 95. Genmab Business Overview Table 96. Genmab Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Genmab Multiple Sclerosis (MS) Drugs Product Portfolio Table 98. Genmab Recent Development Table 99. Five Prime Therapeutics Company Information Table 100. Five Prime Therapeutics Business Overview Table 101. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio Table 103. Five Prime Therapeutics Recent Development Table 104. Fast Forward Llc Company Information Table 105. Fast Forward Llc Business Overview Table 106. Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Portfolio Table 108. Fast Forward Llc Recent Development Table 109. Daiichi Sankyo Company Information Table 110. Daiichi Sankyo Business Overview Table 111. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Portfolio Table 113. Daiichi Sankyo Recent Development Table 114. Cinnagen Company Information Table 115. Cinnagen Business Overview Table 116. Cinnagen Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Cinnagen Multiple Sclerosis (MS) Drugs Product Portfolio Table 118. Cinnagen Recent Development Table 119. Biogen Idec Company Information Table 120. Biogen Idec Business Overview Table 121. Biogen Idec Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Biogen Idec Multiple Sclerosis (MS) Drugs Product Portfolio Table 123. Biogen Idec Recent Development Table 124. Bayhill Therapeutics Company Information Table 125. Bayhill Therapeutics Business Overview Table 126. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio Table 128. Bayhill Therapeutics Recent Development Table 129. Artielle Immunotherapeutics Company Information Table 130. Artielle Immunotherapeutics Business Overview Table 131. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio Table 133. Artielle Immunotherapeutics Recent Development Table 134. Apitope Company Information Table 135. Apitope Business Overview Table 136. Apitope Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Apitope Multiple Sclerosis (MS) Drugs Product Portfolio Table 138. Apitope Recent Development Table 139. Antisense Therapeutics Company Information Table 140. Antisense Therapeutics Business Overview Table 141. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio Table 143. Antisense Therapeutics Recent Development Table 144. North America Multiple Sclerosis (MS) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 145. North America Multiple Sclerosis (MS) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 146. North America Multiple Sclerosis (MS) Drugs Sales by Type (2021-2026) & (W Units) Table 147. North America Multiple Sclerosis (MS) Drugs Sales by Type (2027-2032) & (W Units) Table 148. North America Multiple Sclerosis (MS) Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 149. North America Multiple Sclerosis (MS) Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 150. North America Multiple Sclerosis (MS) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 151. North America Multiple Sclerosis (MS) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 152. North America Multiple Sclerosis (MS) Drugs Sales by Application (2021-2026) & (W Units) Table 153. North America Multiple Sclerosis (MS) Drugs Sales by Application (2027-2032) & (W Units) Table 154. North America Multiple Sclerosis (MS) Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 155. North America Multiple Sclerosis (MS) Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 156. North America Multiple Sclerosis (MS) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 157. North America Multiple Sclerosis (MS) Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 158. North America Multiple Sclerosis (MS) Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 159. North America Multiple Sclerosis (MS) Drugs Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 160. North America Multiple Sclerosis (MS) Drugs Sales by Country (2021-2026) & (W Units) Table 161. North America Multiple Sclerosis (MS) Drugs Sales by Country (2027-2032) & (W Units) Table 162. North America Multiple Sclerosis (MS) Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 163. North America Multiple Sclerosis (MS) Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 164. United States Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 165. Canada Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 166. Mexico Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 167. Europe Multiple Sclerosis (MS) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 168. Europe Multiple Sclerosis (MS) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 169. Europe Multiple Sclerosis (MS) Drugs Sales by Type (2021-2026) & (W Units) Table 170. Europe Multiple Sclerosis (MS) Drugs Sales by Type (2027-2032) & (W Units) Table 171. Europe Multiple Sclerosis (MS) Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 172. Europe Multiple Sclerosis (MS) Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 173. Europe Multiple Sclerosis (MS) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 174. Europe Multiple Sclerosis (MS) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 175. Europe Multiple Sclerosis (MS) Drugs Sales by Application (2021-2026) & (W Units) Table 176. Europe Multiple Sclerosis (MS) Drugs Sales by Application (2027-2032) & (W Units) Table 177. Europe Multiple Sclerosis (MS) Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 178. Europe Multiple Sclerosis (MS) Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 179. Europe Multiple Sclerosis (MS) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 180. Europe Multiple Sclerosis (MS) Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 181. Europe Multiple Sclerosis (MS) Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 182. Europe Multiple Sclerosis (MS) Drugs Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 183. Europe Multiple Sclerosis (MS) Drugs Sales by Country (2021-2026) & (W Units) Table 184. Europe Multiple Sclerosis (MS) Drugs Sales by Country (2027-2032) & (W Units) Table 185. Europe Multiple Sclerosis (MS) Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 186. Europe Multiple Sclerosis (MS) Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 187. Germany Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 188. France Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 189. U.K. Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 190. Italy Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 191. Russia Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 192. Spain Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 193. Netherlands Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 194. Switzerland Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 195. Sweden Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 196. Poland Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 197. China Multiple Sclerosis (MS) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 198. China Multiple Sclerosis (MS) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 199. China Multiple Sclerosis (MS) Drugs Sales by Type (2021-2026) & (W Units) Table 200. China Multiple Sclerosis (MS) Drugs Sales by Type (2027-2032) & (W Units) Table 201. China Multiple Sclerosis (MS) Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 202. China Multiple Sclerosis (MS) Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 203. China Multiple Sclerosis (MS) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 204. China Multiple Sclerosis (MS) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 205. China Multiple Sclerosis (MS) Drugs Sales by Application (2021-2026) & (W Units) Table 206. China Multiple Sclerosis (MS) Drugs Sales by Application (2027-2032) & (W Units) Table 207. China Multiple Sclerosis (MS) Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 208. China Multiple Sclerosis (MS) Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 209. Asia Multiple Sclerosis (MS) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 210. Asia Multiple Sclerosis (MS) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 211. Asia Multiple Sclerosis (MS) Drugs Sales by Type (2021-2026) & (W Units) Table 212. Asia Multiple Sclerosis (MS) Drugs Sales by Type (2027-2032) & (W Units) Table 213. Asia Multiple Sclerosis (MS) Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 214. Asia Multiple Sclerosis (MS) Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 215. Asia Multiple Sclerosis (MS) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 216. Asia Multiple Sclerosis (MS) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 217. Asia Multiple Sclerosis (MS) Drugs Sales by Application (2021-2026) & (W Units) Table 218. Asia Multiple Sclerosis (MS) Drugs Sales by Application (2027-2032) & (W Units) Table 219. Asia Multiple Sclerosis (MS) Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 220. Asia Multiple Sclerosis (MS) Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 221. Asia Multiple Sclerosis (MS) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 222. Asia Multiple Sclerosis (MS) Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 223. Asia Multiple Sclerosis (MS) Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 224. Asia Multiple Sclerosis (MS) Drugs Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 225. Asia Multiple Sclerosis (MS) Drugs Sales by Country (2021-2026) & (W Units) Table 226. Asia Multiple Sclerosis (MS) Drugs Sales by Country (2027-2032) & (W Units) Table 227. Asia Multiple Sclerosis (MS) Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 228. Asia Multiple Sclerosis (MS) Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 229. Japan Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 230. South Korea Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 231. India Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 232. Australia Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 233. Taiwan Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 234. Southeast Asia Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 235. SAMEA Multiple Sclerosis (MS) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 236. SAMEA Multiple Sclerosis (MS) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 237. SAMEA Multiple Sclerosis (MS) Drugs Sales by Type (2021-2026) & (W Units) Table 238. SAMEA Multiple Sclerosis (MS) Drugs Sales by Type (2027-2032) & (W Units) Table 239. SAMEA Multiple Sclerosis (MS) Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 240. SAMEA Multiple Sclerosis (MS) Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 241. SAMEA Multiple Sclerosis (MS) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 242. SAMEA Multiple Sclerosis (MS) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 243. SAMEA Multiple Sclerosis (MS) Drugs Sales by Application (2021-2026) & (W Units) Table 244. SAMEA Multiple Sclerosis (MS) Drugs Sales by Application (2027-2032) & (W Units) Table 245. SAMEA Multiple Sclerosis (MS) Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 246. SAMEA Multiple Sclerosis (MS) Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 247. SAMEA Multiple Sclerosis (MS) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 248. SAMEA Multiple Sclerosis (MS) Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 249. SAMEA Multiple Sclerosis (MS) Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 250. SAMEA Multiple Sclerosis (MS) Drugs Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 251. SAMEA Multiple Sclerosis (MS) Drugs Sales by Country (2021-2026) & (W Units) Table 252. SAMEA Multiple Sclerosis (MS) Drugs Sales by Country (2027-2032) & (W Units) Table 253. SAMEA Multiple Sclerosis (MS) Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 254. SAMEA Multiple Sclerosis (MS) Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 255. Brazil Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 256. Argentina Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 257. Chile Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 258. Colombia Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 259. Peru Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 260. Saudi Arabia Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 261. Israel Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 262. UAE Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 263. Turkey Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 264. Iran Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 265. Egypt Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Table 266. Key Raw Materials Table 267. Raw Materials Key Suppliers Table 268. Multiple Sclerosis (MS) Drugs Distributors List Table 269. Multiple Sclerosis (MS) Drugs Customers List Table 270. Research Programs/Design for This Report Table 271. Authors List of This Report Table 272. Secondary Sources Table 273. Primary Sources List of Figures Figure 1. Multiple Sclerosis (MS) Drugs Image Figure 2. Global Multiple Sclerosis (MS) Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Multiple Sclerosis (MS) Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Copaxone (Glatiramer Acetate, Copolymer 1) Image Figure 5. Firategrast (Sb683699, T-0047) Image Figure 6. Gilenya (Fingolimod, Fty720) Image Figure 7. Tecfidera (Dimethyl Fumarate) Image Figure 8. Aubagio (Teriflunomide) Image Figure 9. Siponimod (Baf312) Image Figure 10. Novantrone (Mitoxantrone) Image Figure 11. Others Image Figure 12. Global Multiple Sclerosis (MS) Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Multiple Sclerosis (MS) Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 14. PPMS Image Figure 15. PRMS Image Figure 16. RRMS Image Figure 17. SPMS Image Figure 18. Global Multiple Sclerosis (MS) Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 19. Global Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Figure 20. Global Multiple Sclerosis (MS) Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 22. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Region (2021-2032) Figure 23. Global Multiple Sclerosis (MS) Drugs Sales (2021-2032) & (W Units) Figure 24. Global Multiple Sclerosis (MS) Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 25. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Region (2021-2032) Figure 26. US & Canada & Mexico Multiple Sclerosis (MS) Drugs Sales YoY (2021-2032) & (W Units) Figure 27. Europe Multiple Sclerosis (MS) Drugs Sales YoY (2021-2032) & (W Units) Figure 28. China Multiple Sclerosis (MS) Drugs Sales YoY (2021-2032) & (W Units) Figure 29. Asia (Excluding China) Multiple Sclerosis (MS) Drugs Sales YoY (2021-2032) & (W Units) Figure 30. South America, Middle East and Africa Multiple Sclerosis (MS) Drugs Sales YoY (2021-2032) & (W Units) Figure 31. Global Multiple Sclerosis (MS) Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 32. Global Multiple Sclerosis (MS) Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 33. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 34. Global Multiple Sclerosis (MS) Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 36. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2021-2032) Figure 37. Global Multiple Sclerosis (MS) Drugs Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 38. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 39. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2021-2032) Figure 40. Global Multiple Sclerosis (MS) Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 41. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 42. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2021-2032) Figure 43. Global Multiple Sclerosis (MS) Drugs Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 44. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 45. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2021-2032) Figure 46. North America Multiple Sclerosis (MS) Drugs Revenue Share by Type (2021-2032) Figure 47. North America Multiple Sclerosis (MS) Drugs Sales Share by Type (2021-2032) Figure 48. North America Multiple Sclerosis (MS) Drugs Revenue Share by Application (2021-2032) Figure 49. North America Multiple Sclerosis (MS) Drugs Sales Share by Application (2021-2032) Figure 50. North America Multiple Sclerosis (MS) Drugs Revenue Share by Country (2021-2032) Figure 51. North America Multiple Sclerosis (MS) Drugs Sales Share by Country (2021-2032) Figure 52. Europe Multiple Sclerosis (MS) Drugs Revenue Share by Type (2021-2032) Figure 53. Europe Multiple Sclerosis (MS) Drugs Sales Share by Type (2021-2032) Figure 54. Europe Multiple Sclerosis (MS) Drugs Revenue Share by Application (2021-2032) Figure 55. Europe Multiple Sclerosis (MS) Drugs Sales Share by Application (2021-2032) Figure 56. Europe Multiple Sclerosis (MS) Drugs Revenue Share by Country (2021-2032) Figure 57. Europe Multiple Sclerosis (MS) Drugs Sales Share by Country (2021-2032) Figure 58. China Multiple Sclerosis (MS) Drugs Revenue Share by Type (2021-2032) Figure 59. China Multiple Sclerosis (MS) Drugs Sales Share by Type (2021-2032) Figure 60. China Multiple Sclerosis (MS) Drugs Revenue Share by Application (2021-2032) Figure 61. China Multiple Sclerosis (MS) Drugs Sales Share by Application (2021-2032) Figure 62. Asia Multiple Sclerosis (MS) Drugs Revenue Share by Type (2021-2032) Figure 63. Asia Multiple Sclerosis (MS) Drugs Sales Share by Type (2021-2032) Figure 64. Asia Multiple Sclerosis (MS) Drugs Revenue Share by Application (2021-2032) Figure 65. Asia Multiple Sclerosis (MS) Drugs Sales Share by Application (2021-2032) Figure 66. Asia Multiple Sclerosis (MS) Drugs Revenue Share by Country (2021-2032) Figure 67. Asia Multiple Sclerosis (MS) Drugs Sales Share by Country (2021-2032) Figure 68. SAMEA Multiple Sclerosis (MS) Drugs Revenue Share by Type (2021-2032) Figure 69. SAMEA Multiple Sclerosis (MS) Drugs Sales Share by Type (2021-2032) Figure 70. SAMEA Multiple Sclerosis (MS) Drugs Revenue Share by Application (2021-2032) Figure 71. SAMEA Multiple Sclerosis (MS) Drugs Sales Share by Application (2021-2032) Figure 72. SAMEA Multiple Sclerosis (MS) Drugs Revenue Share by Country (2021-2032) Figure 73. SAMEA Multiple Sclerosis (MS) Drugs Sales Share by Country (2021-2032) Figure 74. Multiple Sclerosis (MS) Drugs Value Chain Figure 75. Manufacturing Cost Structure Figure 76. Multiple Sclerosis (MS) Drugs Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Years Considered Figure 80. Research Process Figure 81. Key Executives Interviewed

Scope & coverage.

Types
  • Copaxone (Glatiramer Acetate, Copolymer 1)
  • Firategrast (Sb683699, T-0047)
  • Gilenya (Fingolimod, Fty720)
  • Tecfidera (Dimethyl Fumarate)
  • Aubagio (Teriflunomide)
  • Siponimod (Baf312)
  • Novantrone (Mitoxantrone)
  • Others
Applications
  • PPMS
  • PRMS
  • RRMS
  • SPMS
Companies covered
  • Eli Lilly
  • Bayer AG
  • Innate Immunotherapeutics
  • Gw Pharmaceuticals
  • Glaxosmithkline
  • Genzyme
  • Genmab
  • Five Prime Therapeutics
  • Fast Forward Llc
  • Daiichi Sankyo
  • Cinnagen
  • Biogen Idec
  • Bayhill Therapeutics
  • Artielle Immunotherapeutics
  • Apitope
  • Antisense Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Multiple Sclerosis (MS) Drugs Market by Type
  3. 1.2.1 Global Multiple Sclerosis (MS) Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Copaxone (Glatiramer Acetate, Copolymer 1)
  5. 1.2.3 Firategrast (Sb683699, T-0047)
  6. 1.2.4 Gilenya (Fingolimod, Fty720)
  7. 1.2.5 Tecfidera (Dimethyl Fumarate)
  8. 1.2.6 Aubagio (Teriflunomide)
  9. 1.2.7 Siponimod (Baf312)
  10. 1.2.8 Novantrone (Mitoxantrone)
  11. 1.2.9 Others
  12. 1.3 Multiple Sclerosis (MS) Drugs Market by Application
  13. 1.3.1 Global Multiple Sclerosis (MS) Drugs Market Size by Application, 2021 VS 2025 VS 2032
  14. 1.3.2 PPMS
  15. 1.3.3 PRMS
  16. 1.3.4 RRMS
  17. 1.3.5 SPMS
  18. 1.4 Assumptions and Limitations
  19. 1.5 Study Goals and Objectives
2 Multiple Sclerosis (MS) Drugs Market Dynamics
  1. 2.1 Multiple Sclerosis (MS) Drugs Industry Trends
  2. 2.2 Multiple Sclerosis (MS) Drugs Industry Drivers
  3. 2.3 Multiple Sclerosis (MS) Drugs Industry Opportunities and Challenges
  4. 2.4 Multiple Sclerosis (MS) Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Multiple Sclerosis (MS) Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Multiple Sclerosis (MS) Drugs Revenue by Region
  3. 3.2.1 Global Multiple Sclerosis (MS) Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Multiple Sclerosis (MS) Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Multiple Sclerosis (MS) Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Multiple Sclerosis (MS) Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Multiple Sclerosis (MS) Drugs Sales by Region
  9. 3.4.1 Global Multiple Sclerosis (MS) Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Multiple Sclerosis (MS) Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Multiple Sclerosis (MS) Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Multiple Sclerosis (MS) Drugs Revenue by Manufacturers
  2. 4.1.1 Global Multiple Sclerosis (MS) Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Multiple Sclerosis (MS) Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Multiple Sclerosis (MS) Drugs Sales by Manufacturers
  6. 4.2.1 Global Multiple Sclerosis (MS) Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Multiple Sclerosis (MS) Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Multiple Sclerosis (MS) Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Multiple Sclerosis (MS) Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Multiple Sclerosis (MS) Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Multiple Sclerosis (MS) Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Multiple Sclerosis (MS) Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Multiple Sclerosis (MS) Drugs Market CR5 and HHI
  16. 4.8.2 2025 Multiple Sclerosis (MS) Drugs Tier 1, Tier 2, and Tier 3
5 Multiple Sclerosis (MS) Drugs Market by Type
  1. 5.1 Global Multiple Sclerosis (MS) Drugs Revenue by Type
  2. 5.1.1 Global Multiple Sclerosis (MS) Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Multiple Sclerosis (MS) Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Multiple Sclerosis (MS) Drugs Sales by Type
  6. 5.2.1 Global Multiple Sclerosis (MS) Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Multiple Sclerosis (MS) Drugs Sales by Type (2021-2032) & (W Units)
  8. 5.2.3 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Multiple Sclerosis (MS) Drugs Price by Type
6 Multiple Sclerosis (MS) Drugs Market by Application
  1. 6.1 Global Multiple Sclerosis (MS) Drugs Revenue by Application
  2. 6.1.1 Global Multiple Sclerosis (MS) Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Multiple Sclerosis (MS) Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Multiple Sclerosis (MS) Drugs Sales by Application
  6. 6.2.1 Global Multiple Sclerosis (MS) Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Multiple Sclerosis (MS) Drugs Sales by Application (2021-2032) & (W Units)
  8. 6.2.3 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Multiple Sclerosis (MS) Drugs Price by Application
7 Company Profiles
  1. 7.1 Eli Lilly
  2. 7.1.1 Eli Lilly Company Information
  3. 7.1.2 Eli Lilly Business Overview
  4. 7.1.3 Eli Lilly Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Eli Lilly Multiple Sclerosis (MS) Drugs Product Portfolio
  6. 7.1.5 Eli Lilly Recent Developments
  7. 7.2 Bayer AG
  8. 7.2.1 Bayer AG Company Information
  9. 7.2.2 Bayer AG Business Overview
  10. 7.2.3 Bayer AG Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Bayer AG Multiple Sclerosis (MS) Drugs Product Portfolio
  12. 7.2.5 Bayer AG Recent Developments
  13. 7.3 Innate Immunotherapeutics
  14. 7.3.1 Innate Immunotherapeutics Company Information
  15. 7.3.2 Innate Immunotherapeutics Business Overview
  16. 7.3.3 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
  18. 7.3.5 Innate Immunotherapeutics Recent Developments
  19. 7.4 Gw Pharmaceuticals
  20. 7.4.1 Gw Pharmaceuticals Company Information
  21. 7.4.2 Gw Pharmaceuticals Business Overview
  22. 7.4.3 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Portfolio
  24. 7.4.5 Gw Pharmaceuticals Recent Developments
  25. 7.5 Glaxosmithkline
  26. 7.5.1 Glaxosmithkline Company Information
  27. 7.5.2 Glaxosmithkline Business Overview
  28. 7.5.3 Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Portfolio
  30. 7.5.5 Glaxosmithkline Recent Developments
  31. 7.6 Genzyme
  32. 7.6.1 Genzyme Company Information
  33. 7.6.2 Genzyme Business Overview
  34. 7.6.3 Genzyme Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Genzyme Multiple Sclerosis (MS) Drugs Product Portfolio
  36. 7.6.5 Genzyme Recent Developments
  37. 7.7 Genmab
  38. 7.7.1 Genmab Company Information
  39. 7.7.2 Genmab Business Overview
  40. 7.7.3 Genmab Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Genmab Multiple Sclerosis (MS) Drugs Product Portfolio
  42. 7.7.5 Genmab Recent Developments
  43. 7.8 Five Prime Therapeutics
  44. 7.8.1 Five Prime Therapeutics Company Information
  45. 7.8.2 Five Prime Therapeutics Business Overview
  46. 7.8.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
  48. 7.8.5 Five Prime Therapeutics Recent Developments
  49. 7.9 Fast Forward Llc
  50. 7.9.1 Fast Forward Llc Company Information
  51. 7.9.2 Fast Forward Llc Business Overview
  52. 7.9.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Portfolio
  54. 7.9.5 Fast Forward Llc Recent Developments
  55. 7.10 Daiichi Sankyo
  56. 7.10.1 Daiichi Sankyo Company Information
  57. 7.10.2 Daiichi Sankyo Business Overview
  58. 7.10.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Portfolio
  60. 7.10.5 Daiichi Sankyo Recent Developments
  61. 7.11 Cinnagen
  62. 7.11.1 Cinnagen Company Information
  63. 7.11.2 Cinnagen Business Overview
  64. 7.11.3 Cinnagen Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Cinnagen Multiple Sclerosis (MS) Drugs Product Portfolio
  66. 7.11.5 Cinnagen Recent Developments
  67. 7.12 Biogen Idec
  68. 7.12.1 Biogen Idec Company Information
  69. 7.12.2 Biogen Idec Business Overview
  70. 7.12.3 Biogen Idec Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Biogen Idec Multiple Sclerosis (MS) Drugs Product Portfolio
  72. 7.12.5 Biogen Idec Recent Developments
  73. 7.13 Bayhill Therapeutics
  74. 7.13.1 Bayhill Therapeutics Company Information
  75. 7.13.2 Bayhill Therapeutics Business Overview
  76. 7.13.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
  78. 7.13.5 Bayhill Therapeutics Recent Developments
  79. 7.14 Artielle Immunotherapeutics
  80. 7.14.1 Artielle Immunotherapeutics Company Information
  81. 7.14.2 Artielle Immunotherapeutics Business Overview
  82. 7.14.3 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
  84. 7.14.5 Artielle Immunotherapeutics Recent Developments
  85. 7.15 Apitope
  86. 7.15.1 Apitope Company Information
  87. 7.15.2 Apitope Business Overview
  88. 7.15.3 Apitope Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Apitope Multiple Sclerosis (MS) Drugs Product Portfolio
  90. 7.15.5 Apitope Recent Developments
  91. 7.16 Antisense Therapeutics
  92. 7.16.1 Antisense Therapeutics Company Information
  93. 7.16.2 Antisense Therapeutics Business Overview
  94. 7.16.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
  96. 7.16.5 Antisense Therapeutics Recent Developments
8 North America
  1. 8.1 North America Multiple Sclerosis (MS) Drugs Market Size by Type
  2. 8.1.1 North America Multiple Sclerosis (MS) Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Multiple Sclerosis (MS) Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Multiple Sclerosis (MS) Drugs Price by Type (2021-2032)
  5. 8.2 North America Multiple Sclerosis (MS) Drugs Market Size by Application
  6. 8.2.1 North America Multiple Sclerosis (MS) Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Multiple Sclerosis (MS) Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Multiple Sclerosis (MS) Drugs Price by Application (2021-2032)
  9. 8.3 North America Multiple Sclerosis (MS) Drugs Market Size by Country
  10. 8.3.1 North America Multiple Sclerosis (MS) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Multiple Sclerosis (MS) Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Multiple Sclerosis (MS) Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Multiple Sclerosis (MS) Drugs Market Size by Type
  2. 9.1.1 Europe Multiple Sclerosis (MS) Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Multiple Sclerosis (MS) Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Multiple Sclerosis (MS) Drugs Price by Type (2021-2032)
  5. 9.2 Europe Multiple Sclerosis (MS) Drugs Market Size by Application
  6. 9.2.1 Europe Multiple Sclerosis (MS) Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Multiple Sclerosis (MS) Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Multiple Sclerosis (MS) Drugs Price by Application (2021-2032)
  9. 9.3 Europe Multiple Sclerosis (MS) Drugs Market Size by Country
  10. 9.3.1 Europe Multiple Sclerosis (MS) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Multiple Sclerosis (MS) Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Multiple Sclerosis (MS) Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Multiple Sclerosis (MS) Drugs Market Size by Type
  2. 10.1.1 China Multiple Sclerosis (MS) Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Multiple Sclerosis (MS) Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Multiple Sclerosis (MS) Drugs Price by Type (2021-2032)
  5. 10.2 China Multiple Sclerosis (MS) Drugs Market Size by Application
  6. 10.2.1 China Multiple Sclerosis (MS) Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Multiple Sclerosis (MS) Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Multiple Sclerosis (MS) Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Multiple Sclerosis (MS) Drugs Market Size by Type
  2. 11.1.1 Asia Multiple Sclerosis (MS) Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Multiple Sclerosis (MS) Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Multiple Sclerosis (MS) Drugs Price by Type (2021-2032)
  5. 11.2 Asia Multiple Sclerosis (MS) Drugs Market Size by Application
  6. 11.2.1 Asia Multiple Sclerosis (MS) Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Multiple Sclerosis (MS) Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Multiple Sclerosis (MS) Drugs Price by Application (2021-2032)
  9. 11.3 Asia Multiple Sclerosis (MS) Drugs Market Size by Country
  10. 11.3.1 Asia Multiple Sclerosis (MS) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Multiple Sclerosis (MS) Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Multiple Sclerosis (MS) Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Multiple Sclerosis (MS) Drugs Market Size by Type
  2. 12.1.1 SAMEA Multiple Sclerosis (MS) Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Multiple Sclerosis (MS) Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Multiple Sclerosis (MS) Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Multiple Sclerosis (MS) Drugs Market Size by Application
  6. 12.2.1 SAMEA Multiple Sclerosis (MS) Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Multiple Sclerosis (MS) Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Multiple Sclerosis (MS) Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Multiple Sclerosis (MS) Drugs Market Size by Country
  10. 12.3.1 SAMEA Multiple Sclerosis (MS) Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Multiple Sclerosis (MS) Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Multiple Sclerosis (MS) Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Multiple Sclerosis (MS) Drugs Value Chain Analysis
  2. 13.1.1 Multiple Sclerosis (MS) Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Multiple Sclerosis (MS) Drugs Production Mode & Process
  6. 13.2 Multiple Sclerosis (MS) Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Multiple Sclerosis (MS) Drugs Distributors
  9. 13.2.3 Multiple Sclerosis (MS) Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst